Dr. Annette Doherty is the new President of the Royal Society of Chemistry (RSC) and will take over the office in July 2024 from the current President, Professor Gill Reid, University of Southampton, UK. Her term went from 2022 to 2024.
Professor Robert Mokaya, University of Nottingham, UK, has been chosen as President-Elect. He will become President once Annette Doherty has completed her term in July 2026. He will be the first Black president of the RSC.
Annette Doherty has expressed her commitment to maximizing the impact of the RSC for the entire chemical sciences community, emphasizing its vital societal role and future transformative potential.
Annette Doherty studied chemistry and received her Ph.D. in organic synthesis from Imperial College London, UK. She conducted postdoctoral research on a NATO Fellowship at the Ohio State University, Columbus, USA.
Annette Doherty has held a number of positions in the pharmaceutical industry, including at Warner-Lambert, Pfizer, and most recently GlaxoSmithKline, where she was Senior Vice President, Global Head of Product Development and Clinical Supply. She has been directly involved in the research, development, and launch of over 30 new medicines for respiratory, infectious diseases, cancer, and inflammatory conditions.
Annette Doherty is a Non-Executive Director of Cambridge University Hospitals NHS Foundation Trust and a Member of the UK’s scientific advisory group, the Nucleic Acid Therapy Accelerator. In 2021, she was appointed to the Board of Trustees of the RSC. Doherty has published more than 100 scientific articles throughout her career and is a co-inventor on more than 30 patents. In 2009, she was appointed an Officer of the British Empire (OBE) for services to the pharmaceutical sector.
Selected Publications
- Relationship between Phosphodiesterase Type 4 Inhibition and Anti-Inflammatory Activity of CI-1044 in Rat Airways,
Marie-Pierre Pruniaux, Vincent Lagente, Malika Ouaged, Bernadette Bertin, François Moreau, Christine Julien-Larose, Marie-Noelle Rocher, Christelle Leportier, Brigitte Martin, Anita Bouget, Jean-Pierre Dubuit, Catherine Burnouf, Annette M. Doherty, Claude P. Bertrand,
Fundam. Clin. Pharmacol. 2010, 24, 72–83.
https://doi.org/10.1111/j.1472-8206.2009.00725.x - The Discovery of the Benzhydroxamate MEK Inhibitors CI-1040 and PD 0325901,
Stephen D. Barrett, Alexander J. Bridges, David T. Dudley, Alan R. Saltiel, James H. Fergus, Cathlin M. Flamme, Amy M. Delaney, Michael Kaufman, Sophie LePage, Wilbur R. Leopold, Sally A. Przybranowski, Judith Sebolt-Leopold, Keri Van Becelaere, Annette M. Doherty, Robert M. Kennedy, Dan Marston, W. Allen Howard Jr., Yvonne Smith, Joseph S. Warmus, Haile Tecle,
Bioorg. Med. Chem. Lett. 2008, 6501–6504.
https://doi.org/10.1016/j.bmcl.2008.10.054 - Role of Nerve Growth Factor in the Trinitrobenzene Sulfonic Acid-Induced Colonic Hypersensitivity,
Laure Delafoy, Frederic Raymond, Annette M. Doherty, Alain Eschalier, Laurent Diop,
Pain 2003, 105, 489–497.
https://doi.org/10.1016/S0304-3959(03)00266-5 - Pregabalin (CI-1008) Inhibits the Trinitrobenzene Sulfonic Acid-Induced Chronic Colonic Allodynia in the Rat,
Laurent Diop, Frederic Raymond, Helene Fargeau, Francine Petoux, Maria Chovet, Annette M. Doherty,
J. Pharmacol. Exp. Ther. 2002, 302, 1013–1022.
https://doi.org/10.1124/jpet.302.3.1013
